The safety and effectiveness of the experimental drug E2609 will be tested in participants with subjective memory complaints and mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease in this Phase I trial. E2609 has been shown to reduce the amount of harmful beta-amyloid in the brain by inhibiting an enzyme that leads to its accumulation.
|Min Age||Max Age||Gender||Healthy Volunteers|
Participants will take either a placebo or one of several different doses of the study drug. The pharmacokinetics of E2609 and drug effects will be evaluated using cerebrospinal fluid biomarkers and cognitive and psychological measures. E2609 has been shown to reduce the amount of harmful beta-amyloid in the brain by inhibiting an enzyme that leads to its accumulation.
Fore more information about this study, contact Eisai Medical Services at 1-888-422-4743.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 34.1425078, -118.255075
Geolocation is 39.2903848, -76.6121893
Olukemi Olugemo, MD
PARAEXEL International-EPCU Baltimore
Eisai Medical Services